{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:21:44Z","timestamp":1793071304476,"version":"4.5.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Chronic periaortitis (CP) is a rare autoimmune disease without effective treatment. By analyzing the serum bile acid spectrum in 28 CP patients with the ultra-performance liquid chromatography-tandem mass spectrometry, we found that the bile acids were significantly altered in CP patients, with significant increases in chenodeoxycholic acid (CDCA) and glycochenodeoxycholic acid (GCDCA) and decrease in deoxycholic acid (DCA). Signaling pathway enrichment analysis from the RNA sequencing results suggested that the altered gene sets in PBMC of CP patients were associated with bile acid metabolism. Furthermore, we found that pathological concentration of CDCA could significantly inhibited IL-6 expression in RAW 264.7 cells after LPS stimulation. Since CDCA is a well-known natural high-affinity ligand for the bile acid receptor farnesoid-x-receptor (FXR) while GW4064 is the synthetic specific agonist of this receptor, we then revealed that GW4064 significantly decreased IL-6 expression in RAW 264.7 cells and bone marrow-derived macrophages but not in FXR\n                    <jats:sup>-\/-<\/jats:sup>\n                    macrophages upon LPS stimulation. The western blot results with the anti-FXR antibody showed significantly increased expression in the nuclear proportion, suggesting that FXR agonist promoted the transportation of FXR into the nucleus but did not increase the FXR expression in macrophages. Dual-luciferase report assay and ChIP assay demonstrated that upon activation, FXR could directly bind to the promoter site of IL-6, leading to the decreased expression of IL-6. Thus, bile acids, especially CDCA, may operate to damp inflammation\n                    <jats:italic>via<\/jats:italic>\n                    FXR-mediated downregulation of IL-6 in mononuclear cells and provide a protective mechanism for CP patients.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.632864","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T02:14:04Z","timestamp":1619057644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Bile Acids Elevated in Chronic Periaortitis Could Activate Farnesoid-X-Receptor to Suppress IL-6 Production by Macrophages"],"prefix":"10.3389","volume":"12","author":[{"given":"Shan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"B1","first-page":"25","article-title":"Bile Acids in Regulation of Inflammation and Immunity: Friend or Foe","author":"Zhu","year":"","journal-title":"Clin Exp Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.09.008","article-title":"Bile Acids Control Inflammation and Metabolic Disorder Through Inhibition of NLRP3 Inflammasome","volume":"45","author":"Guo","year":"2016","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(76)92827-0","article-title":"Chenodeoxycholic-Acid Treatment of Rheumatoid Arthritis","volume":"307","author":"Bruusgaard","year":"1976","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90855-S","article-title":"Immunosuppressive Properties of Chenodeoxycholic and Ursodeoxycholic Acids in the Mouse","volume":"103","author":"Calmus","year":"1992","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile Acids: Natural Ligands for an Orphan Nuclear Receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1785-z","article-title":"Bile Acid Metabolites Control TH 17 and T Reg Cell Differentiation","volume":"576","author":"Hang","year":"2019","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01853","article-title":"Bile Acids Activated Receptors Regulate Innate Immunity","volume":"9","author":"Fiorucci","year":"2018","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cell.2016.08.001","article-title":"Bile Acid Analog Intercepts Liver Fibrosis","volume":"166","author":"De Magalhaes Filho","year":"2016","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1524890113","article-title":"Obeticholic Acid, a Synthetic Bile Acid Agonist of the Farnesoid X Receptor, Attenuates Experimental Autoimmune Encephalomyelitis","volume":"113","author":"Ho","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00117","article-title":"New Therapeutic Targets in Autoimmune Cholangiopathies","volume":"7","author":"Gerussi","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.03.011","article-title":"Autoimmune Aspects of Chronic Periaortitis","volume":"5","author":"Vaglio","year":"2006","journal-title":"Autoimmun Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal Fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1365-2559.1994.tb01267.x","article-title":"The Distribution of Adhesion Molecules in Chronic Periaortitis","volume":"24","author":"Ramshaw","year":"1994","journal-title":"Histopathology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21698","article-title":"Chronic Periaortitis and HLA\u2013DRB1* 03: Another Clue to an Autoimmune Origin","volume":"55","author":"Martorana","year":"2006","journal-title":"Arthritis Care Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.38032","article-title":"Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis","volume":"65","author":"Vaglio","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz240","article-title":"NetworkAnalyst 3.0: A Visual Analytics Platform for Comprehensive Gene Expression Profiling and Meta-Analysis","volume":"47","author":"Zhou","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.7b00134","article-title":"Chemoproteomic Profiling of Bile Acid Interacting Proteins","volume":"3","author":"Zhuang","year":"2017","journal-title":"ACS Cent Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3312","article-title":"Transcriptional Integration of Metabolism by the Nuclear Sterol-Activated Receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800590807","article-title":"Inflammatory Aneurysms of the Abdominal Aorta","volume":"59","author":"Walker","year":"1972","journal-title":"Br J Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2559.1984.tb02371.x","article-title":"Chronic Periaortitis and Periarteritis","volume":"8","author":"Mitchinson","year":"1984","journal-title":"Histopathology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60934-3","article-title":"Prednisone Versus Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis: An Open-Label Randomised Controlled Trial","author":"Vaglio","year":"9788","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203267","article-title":"Methotrexate Plus Prednisone in Patients With Relapsing Idiopathic Retroperitoneal Fibrosis","volume":"72","author":"Alberici","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200148","article-title":"Cyclophosphamide is a Highly Effective and Safe Induction Therapy in Chronic Periaortitis: A Long-Term Follow-Up of 35 Patients With Chronic Periaortitis","volume":"71","author":"Binder","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B25","article-title":"Efficacy of Infliximab in a Patient With Refractory Idiopathic Retroperitoneal Fibrosis","volume":"30","author":"Catanoso","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201166","article-title":"Rituximab Therapy for Chronic Periaortitis","volume":"71","author":"Maritati","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut Microbiota and Intestinal FXR Mediate the Clinical Benefits of Metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T02:14:07Z","timestamp":1619057647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2021.632864"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.632864","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"article-number":"632864"}}